1. Home
  2. /
  3. Projects
  4. /
  5. Page 2

Ongoing

Tuberculosis Vaccine Accelerator Council

In January 2023, WHO’s Director-General announced plans to establish a TB vaccine accelerator Council to facilitate the development, testing, authorization, and use of new TB vaccines, drawing on lessons learned from the response to the COVID-19 pandemic. The establishment meeting of the Council took place on 20 September 2023, on the occasion of the 78th session of the United Nations General Assembly, in the lead up to the Second United Nations High-level Meeting on TB.The Council is anticipated to work in multiple ways. These includeidentifying needs for, and types of innovative sustainable financial solutions, as well as partnerships between the public, private and philanthropic sectors that can expedite the translation of science into TB vaccines, and ensure their equitable access once available; identifying market solutions to incentivize TB vaccine development, and to ensure that the R&D ecosystem is positioned to rapidly manufacture and distribute vaccines equitably and at scale, once they are available; and advocating with decision makers in the public, private, philanthropy and other relevant sectors to strengthen commitment and concerted action to develop and expand access to novel effective TB vaccines, including through political platforms such as the African Union, ASEAN, BRICS, G20, G7 and others.

Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV

This project will inform tuberculosis (TB) prevention efforts by estimating the health impact of novel tuberculosis vaccines on TB burden in people living with HIV (PLHIV) using a novel Mycobacterium tuberculosis transmission model. HIV confers the largest relative risk of TB, and new TB vaccines could be an important tool to prevent TB; however, modelling studies have not systematically investigated how new vaccines will affect TB burden in PLHIV. In stage 1 of this project, we aim to investigate TB vaccine impact in PLHIV where vaccine product characteristics and delivery vary by recipient HIV status. In stage 2, we aim to quantify how complex vaccine targeting strategies and incorporating additional granularity in HIV/AIDS natural history might affect vaccine impact estimates in PLHIV

New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?

With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden

FAST-TB MOD

FAST-TB population and cost-effectiveness modelling core: This project will accelerate tuberculosis (TB) research translation by using mathematical modelling to address key priority questions as part of FAST TB, linking an expanded state-of-the-art modelling framework with country level data and cross consortium communication around new TB treatment regimens, diagnostics and other interventions.

Preparing the landscape for TB vaccines: South Africa’s strategic planning

The South African TB Think Tank is a national collaboration of TB stakeholders, including researchers, policymakers, clinicians, and civil society. Chaired by the Chief Director of the National TB Programme (NTP), members consolidate TB research through several technical task teams, providing evidenced-based policy recommendations to the Department of Health. To support the national TB vaccine initiative, the TB Think Tank provided recommendations for the recently released NTP Strategic Plan, 2023-28

Creating evidence to support tuberculosis (TB) national and global decision-makers in reducing the global burden of TB

In strong collaboration, we (India, South Africa, Brazil, Indonesia, UK) will create evidence to strengthen capacity and sustainably support high tuberculosis (TB) burden countries (HBC) and global decision-makers in reducing the global burden of TB, by using modelling tools to address key questions on drug-resistant (DR-)TB, new TB vaccines and other interventions, and extend and apply a state-of-the-art TB model, to estimate the relative health, cost-effectiveness, and budget impact, of new and existing interventions, as well as their optimal combination.

Forecasting TB vaccine demand to support supply and procurement planning

We present insights from two workshops with global health funders, academics, and in country TB and vaccine decision-makers and estimates of potential global demand for TB vaccines using a bottom-up, constrained demand forecasting model. The model was informed by the workshops, publicly available target product profile, landscape assessment of vaccines in development, information from proxy vaccines sourced from the WHO databases and peer reviewed literature, and interviews with TB and vaccine experts
Click to copy link of this header Menu